Crinetics Pharmaceuticals Inc.
Clinical trials sponsored by Crinetics Pharmaceuticals Inc., explained in plain language.
Crinetics Pharmaceuticals Inc.
CRNX
NASDAQ
A biopharmaceutical company developing therapies for endocrine diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill could tame hormone disorder Cushing's syndrome Results expected Oct 2026 (estimated)
- New pill may help adults with rare adrenal disorder cut back on steroids Results expected May 2027 (estimated)
- New targeted drug trial opens for patients with Hard-to-Treat neuroendocrine cancers Results expected Aug 2027 (estimated)
- New pill aims to tame flushing and diarrhea in rare cancer syndrome Results expected Aug 2027 (estimated)